UroGen Pharma (URGN) 6-K UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

Report of Foreign Private Issuer

Pursuant to Rule13a-16 or15d-16

Under the Securities Exchange Act of 1934

For the month of February, 2018

Commission File Number001-38079

UROGEN PHARMA LTD.

(Translation of registrant’s name into English)

9 Ha’Ta’asiya Street

Ra’anana 4365007, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form20-F or Form40-F.

Form20-F  ☒            Form40-F  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7):  ☐

On February 14, 2018, UroGen Pharma Ltd. issued a press release, a copy of which is furnished as Exhibit 99.1 to this Form6-K.

Exhibit
99.1	Press Release, dated February 14, 2018: UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	UROGEN PHARMA LTD.
February 14, 2018	By:	/s/ Gary S. Titus
		Gary S. Titus
		Chief Financial Officer